Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tivozanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 20/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 4/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 3/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 12/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | BCR | P11274 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 2/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tivozanib SCHEMBL29354604 | 1.00 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL29354238 | 1.00 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL30993908 | 0.99 | KDR (0.98) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL1869882 | 0.99 | KDR (0.98) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL21174286 | 0.98 | KDR (0.97) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL29394095 | 0.98 | KDR (0.97) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5214691 | 0.97 | KDR (0.93) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5209537 | 0.97 | KDR (0.93) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5211590 | 0.95 | KDR (0.90) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5545131 | 0.95 | KDR (0.90) | KDRPDGFRAFLT1FLT4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12059429-B2 | Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-08-13 | — | — | US | claimed |
| EP-2786750-B2 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | EA PHARMA CO LTD (JP) | 2023-06-28 | — | — | EP | claimed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | claimed |
| WO-2021150792-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | MICURX PHARMACEUTICALS, INC. (US) | 2021-07-29 | — | — | WO | claimed |
| CN-108938584-B | Tablet containing VEGF receptor inhibitor Tivozanib salt and preparation method thereof | 湖北欣瑞康医药科技有限公司 | 2021-01-26 | — | — | CN | claimed |
| US-20200155594-A1 | HORNERIN: A NOVEL NON-VEGF MEDIATED ANGIOGENIC PROTEIN EXPRESSED IN BOTH HUMAN AND MOUSE ANGIOGENIC ENDOTHELIAL CELLS AND HUMAN PANCREATIC CANCER CELLS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-21 | — | — | US | claimed |
| WO-2017037220-A1 | ROS1 POSITIVE CANCER TREATMENT | IST AUSTRIA (AT) | 2017-03-09 | — | — | WO | claimed |
| EP-2786750-B1 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | AJINOMOTO KK (JP) | 2016-06-08 | — | — | EP | claimed |
| EP-2036557-B1 | ANTITUMOR AGENT FOR THYROID CANCER | EISAI R&D MAN CO LTD (JP) | 2015-10-21 | — | — | EP | claimed |
| EP-2632458-B1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | NOVARTIS AG (CH) | 2015-08-12 | — | — | EP | claimed |
| EP-1559715-B1 | N-{2-CHLORO-4-[(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL}-N'-(5-METHYL-3-ISOXAZOLYL)UREA SALT IN CRYSTALLINE FORM | KIRIN BREWERY (JP) | 2007-09-26 | — | — | EP | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| US-7166722-B2 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-23 | — | — | US | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| EP-1652847-A1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-03 | — | — | EP | claimed |
| US-20060052415-A1 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-03-09 | — | — | US | claimed |
| EP-1382604-B1 | QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE | KIRIN BREWERY (JP) | 2005-12-28 | — | — | EP | claimed |
| EP-1559715-A1 | N-[2-CHLORO-4-(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL]-N'-(5-METHYL-3-ISOXAZOLYL)UREA SALT IN CRYSTALLINE FORM | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-08-03 | — | — | EP | claimed |
| US-6821987-B2 | 4-SUBSTITUTED BY AZOLYLUREIDO-PHENOXY, OR PHENYLTHIO; ANTITUMOR AGENTS; TREATING DIABETIC RETINOPATHY, CHRONIC RHEUMATISM, PSORIASIS, ATHEROSCLEROSIS, | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-23 | — | — | US | claimed |
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | KDR 2/4885FLT1 3/4885FLT4 1/4885 |
| US-20060052415-A1 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form | UACA, REN, TPMT | KDR 421/4885FLT1 1068/4885FLT4 242/4885 |
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | KDR 3455/4885FLT1 2511/4885FLT4 1955/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | KDR 277/4885FLT1 326/4885FLT4 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.